On November 5, 2015 Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, reported that data in six abstracts on the investigational protein therapeutics sotatercept, luspatercept and ACE-1332 will be presented at the 57th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition being held in Orlando, Florida on December 5-8, 2015 (Press release, Acceleron Pharma, NOV 5, 2015, View Source [SID:1234507988]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral presentations
Title: Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study (Abstract #92)
Session: 637. Myelodysplastic Syndromes – Clinical Studies: New Therapeutic Approaches
Date: Saturday, December 5th
Time: 12:15 pm EST (Orange County Convention Center, W331)
Title: TGFβ1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis (Abstract #605)
Session: 635. Myeloproliferative Syndromes: Basic Science II
Date: Monday, December 7th
Time: 11:30 am EST (Orange County Convention Center, W331)
Title: RAP-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in Murine β-Thalassemia (Abstract #751)
Session: 112. Thalassemia and Globin Gene Regulation: Therapeutic Approaches to Thalassemia and Their Mechanisms
Date: Monday, December 7th
Time: 4:35 pm EST (Orange County Convention Center, Valencia A (W415A))
Title: Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study (Abstract #752)
Session: 112. Thalassemia and Globin Gene Regulation: Therapeutic Approaches to Thalassemia and Their Mechanisms
Date: Monday, December 7th
Time: 4:45 pm EST (Orange County Convention Center, Valencia A (W415A))
Poster presentations
Title: Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study (Abstract #2862)
Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Date: Sunday, December 6th
Time: 6:00 – 8:00 pm EST (Orange County Convention Center, Hall A)
Title: Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (Abstract #4241)
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster III
Date: Monday, December 7th
Time: 6:00 – 8:00 pm (EST) (Orange County Convention Center, Hall A)
The posters and presentation slides will be available in the "Publications" section on Acceleron’s website (www.acceleronpharma.com).
About Luspatercept
Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-beta) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Acceleron and Celgene are initiating phase 3 clinical trials that are designed to evaluate the safety and efficacy of luspatercept in patients with myelodysplastic syndromes (the "MEDALIST" study) and in patients with beta-thalassemia (the "BELIEVE" study). For more information, please visit www.clinicaltrials.gov.
About Sotatercept
Sotatercept is an activin receptor type IIA fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-β) superfamily involved in the late stages of erythropoiesis (red blood cell production). Sotatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing sotatercept as part of a global collaboration. Sotatercept is currently in multiple phase 2 clinical trials. For more information, please visit www.clinicaltrials.gov.